Proteomics International Laboratories Addresses ASX Price Query Following Share Surge from $0.16 to $0.22

ASX Issues Price Query After PIQ Shares Rise from $0.16 to $0.22

On 3 July 2026, the ASX issued a formal price query to Proteomics International Laboratories regarding the increase in its share price from $0.16 at the close on 2 July 2026 to $0.22 during trading on 3 July 2026. The query was addressed to company secretary Mr Timothy Luscombe, with a response deadline of 5:30 PM AEST the same day.

Such price queries are standard regulatory procedures designed to ensure listed companies meet their continuous disclosure obligations. Issued under Listing Rule 18.7, they require companies to provide information when unusual price or volume movements occur. Proteomics International was asked to respond to five specific questions concerning potential undisclosed information, reliance on trading exemptions, and authorisation of the response.

Proteomics International Confirms No Undisclosed Market-Sensitive Information

In its reply, Proteomics International Laboratories stated it is not aware of any undisclosed information that could explain the recent trading activity. This directly addresses the main concern of the price query—whether material non-public information might be influencing trading.

This confirmation is important from a compliance standpoint. By denying the existence of undisclosed information, the company was not required to address further questions related to exemptions under Listing Rule 3.1A or the need for an immediate announcement. The company’s board and management indicated no pending deals, regulatory outcomes, or other material developments remain unreleased.

End-of-Financial-Year Market Factors Suggested as Possible Cause

While denying undisclosed information, Proteomics International noted that the trading increase followed the end of the financial year and could reflect broader market factors. The company did not identify any specific cause for the price movement.

The Australian financial year ends on 30 June, a period often marked by heightened market activity as investors adjust portfolios for tax and strategic reasons. Smaller-cap stocks like PIQ can experience price and volume swings during this time that may not be linked to company-specific news. The company acknowledged this possibility without confirming it as the definitive explanation.

Compliance with ASX Listing Rule 3.1 Confirmed

Proteomics International confirmed it is, to the best of its knowledge, fully compliant with ASX Listing Rule 3.1, which mandates immediate disclosure of any information likely to impact the price or value of securities. This rule underpins market integrity in Australia.

The company’s affirmation signals that all material information has been disclosed and that internal governance processes are operating effectively. Such confirmations provide investors and analysts with assurance that the company is not selectively disclosing information.

Response Approved by CEO David Morris and Chairman Dr James Williams

The company confirmed that its response was authorised under its continuous disclosure policy by CEO and Managing Director Mr David Morris and Chairman Dr James Williams, reflecting standard governance practices for ASX-listed companies.

The involvement of both the CEO and Chairman underscores the company’s commitment to fulfilling its market disclosure obligations at the highest governance level.

Implications of the ASX Price Query for Investors

Investors should note that a formal price query does not imply any wrongdoing. It is a routine regulatory tool triggered by significant price movements to ensure transparency. The ASX issued the query promptly on the day of the price rise, demonstrating the efficiency of surveillance systems.

The ASX also reserves the right to release correspondence related to the query to the market, ensuring all participants have equal access to information. This company update fulfills that process. The immediate impact of the response on PIQ’s share price was not publicly evident.

No Trading Halt Required as PIQ Meets Disclosure Obligations

The ASX’s query letter outlined conditions for a possible trading halt if the company failed to respond on time or disclosed undisclosed material information that could not be immediately released. Proteomics International’s timely response confirmed no such information exists, avoiding any suspension of trading.

This compliance allowed uninterrupted trading of PIQ securities, maintaining market continuity.

Overview of Proteomics International Laboratories and Current Status

Proteomics International Laboratories Ltd, based in Perth and part of the PILL Group, specialises in proteomics—the large-scale study of proteins. The company develops diagnostic tools and research services in this field. No operational or financial updates were provided in this announcement.

The price query response did not disclose new contracts, clinical trial results, partnerships, revenue data, or strategic developments. Investors seeking further information are directed to prior company announcements available on the ASX platform. Upcoming operational updates may offer additional insights into the company’s activities and financial position.

Investor Guidance Following Price Query Resolution

With the price query resolved without a trading halt or new material disclosures, investor focus generally returns to the company’s fundamentals and previously announced activities. The share price increase from $0.16 to $0.22 represents a significant percentage change for a smaller-cap stock, though the exact cause remains unconfirmed.

Investors should monitor forthcoming announcements such as quarterly reports, operational updates, or partnership news that may clarify recent trading activity. As always, investors are encouraged to consider all public information alongside their personal financial situations and risk tolerance when evaluating PIQ securities.